Navigation Links
Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets
Date:11/2/2011

CAPE CORAL, Fla., Nov. 2, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk - News) announced that it has reached an agreement in principal with the inventor of a formula that could have life changing results for hundreds of millions of people worldwide afflicted with the disease. It is expected that the formal agreement will be executed in the coming week, at which point details of the product will be released.

Robert deZanger, CEO of Natures Bioceuticals stated, "The implications of this natural medicine formula are mind boggling both in terms of the increased quality of life to the people who need it and the potential revenues to the company. There are over 20 different prescription drugs for this condition currently on the market and many of them have multi-billion dollar annual sales. We are anxious to have the formal closing and transfer of the rights as soon as possible so we can file a patent on the formula. We will then immediately start clinical trials to validate the veracity of the initial study. If the new expanded control group responds in a similar manner to the initial result this should be a product that will have far reaching implications and should generate acquisition interest from the major pharmaceutical and natural product companies. I look forward to further disclosure, in the very near future, pertaining to this exciting formula."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synth
'/>"/>

SOURCE Nature's Bioceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
2. Natures Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
5. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
6. Graphenes quantum leap takes electronics a step closer
7. Avisena Closes $2.5 Million of Debt Capital By Square 1 Bank
8. Cephalon to Release Second Quarter 2011 Earnings Results After the Market Close on August 2, 2011
9. Nanoengineers invent new biomaterial that more closely mimics human tissue
10. UCLA researchers now 1 step closer to controlled engineering of nanocatalysts
11. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... 2015 , ... VetStem Biopharma will be offering weekly private guided tours of ... veterinarians. , The tour and course will be given every Wednesday at 6pm to ... facility. Staff members are welcome to attend with their veterinarian as well. Participants will ...
(Date:7/28/2015)... , July 28, 2015 BioStructures, LLC, ... has hit a milestone of 4,000 implantations of ... 510(k) cleared in early 2014 as a bone ... spine fusion procedures.  This is a distinguished status ... than 6% of new synthetic products have received ...
(Date:7/28/2015)... 2015  Faced with increasing challenges such as ... than symptomatic, the global healthcare industry today is ... of curing or significantly changing the course of ... towards regenerative medicine as a viable alternative. ... human health with the potential to resolve unmet ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn of viscose ... the EU. For instance, it surpassed the EUR 106 million mark (in value terms) ... Germany is a major producer, while Italy is a key consumer. , The ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Revolutionary Bone Graft Exceeds Expectations 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... Incremental Data to be Presented at ASCO GI ... to Oxaliplatin in First-Line Colorectal Cancer Treatment -SOUTH ... Inc. (Nasdaq: PARD ), a biopharmaceutical ... updated efficacy and safety data from its randomized, ...
... a top question of Jatropha developers is, "What impact ... sector and its prominence as a viable, sustainable biofuel?" ... 20 January webinar has been scheduled. As a precursor ... lend crucial answers to hard-hitting inquiries by Jatropha investors. ...
... will be presented at Photonics West 2009PITTSFIELD, Mass., ... international society for optics and photonics, and Laurin ... 67 finalist companies for the 2008 Prism Awards ... photonics industry worldwide. The Prism Awards, introduced for ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 2Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 3Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 4SPIE and Laurin Publishing Announce Prism Awards Finalists 2SPIE and Laurin Publishing Announce Prism Awards Finalists 3
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/2/2015)... , June 25, 2015 ... announced the addition of the "Natural Language ... Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... their offering. The key vendors occupying ... HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... A compound derived from cottonseed could help improve the ... researchers at the University of Michigan Comprehensive Cancer Center ... July issue of the journal Molecular Cancer Therapeutics, could ... to surgically removing the cancer, helping patients preserve vital ...
... water droplets to create adhesive bonds almost as strong as ... , The new beetle-inspired switch, designed by Cornell University engineers, ... -- a millionth of a meter. The switches can be ... Like the transistor, whose varied uses became apparent only following ...
... the National Institute of Allergy and Infectious Diseases (NIAID), ... the surprising discovery that flaviviruses, which cause such serious ... of encephalitis, evade immune system defenses in different ways ... ticks. This finding could lead to new approaches to ...
Cached Biology News:Compound from Chinese medicine shows promise in head and neck cancer 2Compound from Chinese medicine shows promise in head and neck cancer 3Beetle-inspired switch uses water for bonding 2Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 2Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 3
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Biology Products: